Pharmaceutical technology company Pharaoh published information on the interim results of the second phase of the BEXMAB study on Tuesday. The information was made public American Society of Hematologyn (ASH) Annual Meeting.
The study showed improvements in patient treatment outcomes.
According to the company’s release, the overall response rate was 80 percent in the refractory or relapsed HMA-failed MDS patient group.
The observed responses were mainly deep and durable, with 70 percent of patients achieving a complete response, complete bone marrow remission, or partial response.
Four patients have gone on to receive a bone marrow transplant.
The estimated median overall survival time is approximately 13.4 months in the MDS patient group.
The combination of bexmarilimab and azacitidine is well tolerated.
Clever-1 target binding and expression in the bone marrow with increased antigen presentation and the presence of CD8 T and NK cells supports the mechanism of action of bexmarilimab.
“The combination is well tolerated and produces strong and lasting reduction of cancer cells and hematological improvements. This confirms the unique and leading mechanism of action of bexmarilimab in the treatment of MDS and in the field of myeloid cell reprogramming. With this compelling evidence, we are well-positioned to advance to a full Phase 2 efficacy outcome and actively pursue additional regulatory efforts to navigate and refine the BLA filing,” CEO of Faron Juho Jalkanen commented in the announcement.
Faron will hold a virtual webinar to discuss the full analysis of the data on December 10, 2024 at 4:00 p.m.